FI980822A0 - Pharmaceutical composition on the skin or mucosal surface of the active substance or through the skin or mucosa surface - Google Patents

Pharmaceutical composition on the skin or mucosal surface of the active substance or through the skin or mucosa surface

Info

Publication number
FI980822A0
FI980822A0 FI980822A FI980822A FI980822A0 FI 980822 A0 FI980822 A0 FI 980822A0 FI 980822 A FI980822 A FI 980822A FI 980822 A FI980822 A FI 980822A FI 980822 A0 FI980822 A0 FI 980822A0
Authority
FI
Finland
Prior art keywords
skin
pharmaceutical composition
active substance
mucosa
mucosal
Prior art date
Application number
FI980822A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI980822A (en
Inventor
Lise Sylvest Nielsen
Jens Hansen
Original Assignee
Gs Dev Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gs Dev Ab filed Critical Gs Dev Ab
Publication of FI980822A publication Critical patent/FI980822A/en
Publication of FI980822A0 publication Critical patent/FI980822A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI980822A 1995-10-12 1998-04-09 Pharmaceutical composition on the skin or mucosal surface of the active substance or through the skin or mucosa surface FI980822A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK115095 1995-10-12
PCT/DK1996/000437 WO1997013528A1 (en) 1995-10-12 1996-10-11 A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface

Publications (2)

Publication Number Publication Date
FI980822A FI980822A (en) 1998-04-09
FI980822A0 true FI980822A0 (en) 1998-04-09

Family

ID=8101575

Family Applications (1)

Application Number Title Priority Date Filing Date
FI980822A FI980822A0 (en) 1995-10-12 1998-04-09 Pharmaceutical composition on the skin or mucosal surface of the active substance or through the skin or mucosa surface

Country Status (7)

Country Link
EP (1) EP0871489A1 (en)
JP (1) JPH11513393A (en)
AU (1) AU702030B2 (en)
CA (1) CA2231273A1 (en)
FI (1) FI980822A0 (en)
NO (1) NO981633L (en)
WO (1) WO1997013528A1 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440980B1 (en) 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
WO1998047487A1 (en) * 1997-04-17 1998-10-29 Dumex-Alpharma A/S A novel bioadhesive drug delivery system based on liquid crystals
CA2294988C (en) 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
CA2299298A1 (en) * 1997-08-09 1999-02-18 Jane Elizabeth Hilton Compositions for nasal administration
PL333331A1 (en) * 1997-09-09 1999-12-06 Select Release Coated particles, method of producing them and their application
SE9703458D0 (en) * 1997-09-25 1997-09-25 Pharmacia & Upjohn Ab Nicotine compositions and methods of formulation thereof
WO1999060012A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
US7030155B2 (en) 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9827034D0 (en) * 1998-12-10 1999-02-03 Univ Manchester Delivery formulation
JP2003506397A (en) * 1999-08-06 2003-02-18 マックス−デルブルック−セントルム フュア モレキュラー メディツィン Implantable active ingredient depot
AU2012101A (en) * 1999-12-20 2001-07-03 New Pharma Research Sweden Ab Veterinary compositions
DE10057769A1 (en) 2000-11-22 2002-05-23 Beiersdorf Ag Use of a composition for cosmetic or dermatological hair care products, comprises dispersed liquid crystals forming a cubic phase as a base
ES2327397T3 (en) * 2001-04-30 2009-10-29 TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL URIDINE ESTERES PHARMACEUTICALLY ACTIVE.
US7439271B2 (en) * 2001-06-27 2008-10-21 The Gillette Company Reduction of hair growth
US20030124196A1 (en) 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
WO2005021046A1 (en) * 2003-09-01 2005-03-10 Fh Faulding & Co Ltd Compositions and methods for delivery of biologically active agents
EP1768650B1 (en) * 2004-06-04 2008-07-16 Camurus Ab Liquid depot formulations
US8795703B2 (en) 2004-09-28 2014-08-05 Atrium Medical Corporation Stand-alone film and methods for making the same
WO2006036967A1 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Solubilizing a drug for use in a coating
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US8871712B2 (en) 2005-01-14 2014-10-28 Camurus Ab Somatostatin analogue formulations
EP1845942B1 (en) * 2005-01-14 2014-04-09 Camurus Ab Gnrh analogue formulations
KR100983746B1 (en) * 2005-01-14 2010-09-24 카무러스 에이비 Somatostatin analogue formulation
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
ES2343641T3 (en) 2005-01-14 2010-08-05 Camurus Ab TOPIC BIOADHESIVE FORMULATIONS.
CA2595385C (en) 2005-01-21 2011-01-25 Camurus Ab Pharmaceutical lipid compositions
WO2006122022A2 (en) * 2005-05-10 2006-11-16 Novartis Ag Modified release famciclovir pharmaceutical compositions
WO2006131730A1 (en) 2005-06-06 2006-12-14 Camurus Ab Glp-1 analogue formulations
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
WO2007047781A2 (en) 2005-10-15 2007-04-26 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
AU2007311019B2 (en) 2006-10-17 2013-05-16 Nuvo Pharmaceuticals, Inc Diclofenac gel
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
EP2626091B1 (en) 2006-11-06 2016-09-28 Atrium Medical Corporation Coated surgical mesh
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
EP2288898B1 (en) * 2008-06-09 2015-08-12 Boehringer Ingelheim International GmbH Device and method for determining the properties of aerosol formulations
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
US8546450B1 (en) 2009-03-31 2013-10-01 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
US8618164B2 (en) 2009-03-31 2013-12-31 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
WO2010150262A2 (en) * 2009-06-25 2010-12-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Reverse hexagonal mesophases (hii) and uses thereof
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
EP2593141B1 (en) 2010-07-16 2018-07-04 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
PE20150195A1 (en) 2012-05-25 2015-02-27 Camarus Ab SOMATOSTATIN RECEPTOR AGONIST FORMULATIONS
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
AU2013294915C1 (en) 2012-07-26 2019-11-21 Camurus Ab Opioid formulations
EP3612166A4 (en) 2017-04-20 2020-11-04 Zeenar Enterprises Pty Ltd Liquid crystalline dosage form for administering a statin
EP3848052A4 (en) * 2018-09-07 2022-06-08 Farnex Incorporated External preparation comprising non-lamellar liquid crystal-forming lipid
US20210369623A1 (en) * 2018-10-25 2021-12-02 Zeenar Enterprises Pty Ltd Composition that forms liquid crystalline particles
CN111821254B (en) * 2019-04-18 2021-10-15 华东师范大学 Antiviral hydrogel and preparation method and application thereof
CN111759858B (en) * 2020-06-02 2022-09-20 杭州英健生物科技有限公司 PH-sensitive digestive tract mucosa protective gel and application thereof
CN112791047A (en) * 2021-01-15 2021-05-14 中国人民解放军总医院第三医学中心 Resveratrol lamellar liquid crystal and preparation method thereof
CA3235606A1 (en) * 2021-10-19 2023-04-27 Sensach Ab Lipid patch
WO2023189270A1 (en) * 2022-03-28 2023-10-05 富士フイルム株式会社 Biomaterial composition
WO2023189273A1 (en) * 2022-03-28 2023-10-05 富士フイルム株式会社 Biological composition
WO2024068672A1 (en) * 2022-09-26 2024-04-04 Universität Bern Structured lipid compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2631282A1 (en) * 1976-07-12 1978-01-19 Kali Chemie Pharma Gmbh Increasing solubility of pharmaceutical used e.g. in gelatin capsules - by dissolving in fatty acid mono:glyceride cpds. and then rapidly cooling
SE457933B (en) * 1987-07-06 1989-02-13 Larsson Kare PHARMACEUTICAL COMPOSITION INCLUDING A WATER DISPERSED MIXTURE OF LIPIDS, MONOGLYCERIDES AND PHOSPHATIDYLCOLINE AND ITS APPLICATION FOR THE PREPARATION OF A GASTRONIN TESTINALLY EFFECTIVE COMPOSITION
DE69129918T2 (en) * 1990-03-23 1999-02-04 Yoshitomi Pharmaceutical A pharmaceutical preparation that contains poorly water-soluble medicines
DK0752855T3 (en) * 1994-03-30 2000-01-03 Gs Dev Ab Use of fatty acid esters as bioadhesive substances

Also Published As

Publication number Publication date
NO981633D0 (en) 1998-04-08
EP0871489A1 (en) 1998-10-21
AU702030B2 (en) 1999-02-11
JPH11513393A (en) 1999-11-16
CA2231273A1 (en) 1997-04-17
NO981633L (en) 1998-06-04
FI980822A (en) 1998-04-09
AU7279296A (en) 1997-04-30
WO1997013528A1 (en) 1997-04-17

Similar Documents

Publication Publication Date Title
FI980822A0 (en) Pharmaceutical composition on the skin or mucosal surface of the active substance or through the skin or mucosa surface
DE69830095D1 (en) Pharmaceutical, cosmetic or dermo-pharmaceutical patch for the administration of several different active substances
BR9610153A (en) Pharmaceutical formulations
BR9611626A (en) Pharmaceutical formulations
ITMI950568A0 (en) PHARMACEUTICAL FORMULATIONS IN THE FORM OF THIXOTROPIC GEL
NO20021172D0 (en) Pharmaceutical composition
ID24654A (en) OMEPRAZOLA PHARMACEUTICAL FORMULATION
BR9607317A (en) Peptides and pharmaceutical composition
BR9607318A (en) Peptides and pharmaceutical composition
IS5665A (en) Pharmaceutical pressure spray composition
PT907364E (en) PHARMACEUTICAL COMPOSITION OF SUSTAINED LIBERTACAO
NO954486D0 (en) Pharmaceutical formulation basis
NO981008D0 (en) Pharmaceutical formulation
IT1280407B1 (en) APPARATUS FOR THE VAPORIZATION OF INSECTICIDE OR SIMILAR SOLUTIONS
IT1295645B1 (en) APPARATUS FOR THE ELECTRO-EMANATION OF ACTIVE INGREDIENTS.
EE04681B1 (en) 3,6-Half-Ketals of the 9a-Azalides, Method of Preparation and Pharmaceutical Composition
FI964619A (en) Dosage of antiepileptic drugs on the skin
LV11727A (en) Pharmaceutical composition
FI973229A0 (en) New pharmaceutical composition
BR9806083A (en) Pharmaceutical composition for the treatment of hapattite c
FI973280A0 (en) Pharmaceutical composition
TR199600583A2 (en) Increasing the tolerability of amino acids with pharmaceutical activity.
FI973230A (en) New pharmaceutical formulation
BR9606066A (en) Compound and pharmaceutical formulation
BR9605777A (en) Pharmaceutical composition